Cipla Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v3570ugtbln06cx2c143bcco.pdf

Key Takeaways


India Business: The Growth Engine


U.S. Business: The Respiratory Catalyst

Achin Gupta: "We remain very confident in our U.S. business outlook, which is supported by a pipeline of nearly 40 to 50 products to be filed over the next 3 years."

Margins: Back-Half Weighted Recovery

Ashish Adukia: "We expect the EBITDA margins to be in the range of 18.5% to 20% and this would be actually achieved with a sequential improvement quarter-on-quarter with the key improvement being in the second half of the year."

Biosimilars & Complex Generics: The Next Leg

Achin Gupta: "We see biosimilars as a very large and underpenetrated opportunity. And with the recent change in some of the guidelines... we believe this to be an upcoming almost $200 billion opportunity with around 100 such biologics expected to lose exclusivity over the next decade."

Capital Allocation & the M&A Option

Ashish Adukia: "If you were to chase 1 or 2 large transactions, meaningful transactions, this is not a very high amount of cash. So I don't think we are worried about the cash on our books." [16–17]

International Markets: Steady Contributors


Guidance & Commitments

CommitmentSpecificsTimeline
U.S. revenue run rateReach $1 billion run rate, contingent on pipeline maturing (excludes Lanreotide)By end of FY27
FY27 EBITDA margin18.5% to 20%, with sequential QoQ improvement and key step-up in H2FY27 full year
Generic Ventolin launchFirst AB-rated generic with CGT, manufactured at U.S. facilityQ1 FY27 (ramp-up in H2)
Advair approvalPre-approval inspection completed on U.S. facilityDuring FY27
Respiratory filings4 additional assets for filing, including 2 with green propellantOver next 24 months
Peptide launchesSelect launches from 8 filed assetsFY27–28
Biosimilar pipeline buildAdd 1–2 assets each year toward 6–8 in-house assetsOver next 5–8 years
Lanreotide refilingAlternate U.S. site identified; partner remediation in progressEarly next calendar year or Q4 FY27
India growthStrong double-digit, market-beating growthFY27 and FY28
U.S. pipeline filings40–50 products filed, including 12 first-to-files and 8 B2 opportunitiesOver next 3 years
Trade generics launches17 new product launchesFY27
EBITDA margin aspirationSustain 20%+Beyond FY27

Key Metrics

MetricQ4 FY26
Revenue₹6,541 cr, FY26 revenue ₹28,163 cr
EBITDA margin15.2% (excl. other income), FY26 margin 21%
Gross margin65.6% (after material costs), FY26 margin 66%
PAT₹555 cr, 8.5% of sales, effective tax rate 22.2%
R&D spend₹509 cr, 7.8% of revenue; FY26 ₹1,974 cr at 7% of revenue
Total expenses₹3,296 cr, up ~10% YoY; FY26 ₹12,689 cr
Net cash₹10,526 cr, debt incl. lease liabilities ₹614 cr
ROIC22.9% for FY26
One India revenue growth15% YoY, FY26 growth 9% YoY
North America revenue$155 mn, FY26 revenue $780 mn
Albuterol market share19.6% as per IQVIA MAT March '26
One Africa revenue growth14% YoY in USD terms, FY26 growth 7% YoY
EMEU revenuebreached $400 mn mark for FY26
Chronic mix (India)60% as per IQVIA MAT March '26
FY27 EBITDA margin guidance18.5% to 20%, sequential improvement QoQ, key improvement in H2, excludes Lanreotide contribution
U.S. revenue run-rate target$1 bn exit run rate by end of FY27, not full-year revenue